Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended																			6 Months Ended		12 Months Ended
	Dec. 31, 2015		Sep. 26, 2015		Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014	Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Dec. 31, 2015	Dec. 27, 2014	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013	Oct. 22, 2015
Stock Repurchase Program, Authorized Amount	$ 3.3																			$ 3.3
Numerator:
Net income (loss)	$ (107.0)	[1]	$ 112.6	[2]	$ 56.4	[3]	$ (94.9)	[4]	$ 70.2	[5]	$ 96.3	$ 131.7	[6]	$ 48.1	[7]	$ (86.0)	[8]	$ 111.4	[9]	$ 5.6	$ 166.5	$ 128.0	$ 205.3	$ 441.9
Denominator:
Weighted average shares outstanding for basic EPS	144.9		146.3		146.3		140.8		136.3		133.9	133.8		133.7		98.7		94.2		145.6	135.1	139.3	115.1	93.9
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements																				0.5		0.5	0.5	0.6
Weighted average shares outstanding for diluted EPS	144.9		146.9		146.8		140.8		136.8		134.4	134.3		134.3		98.7		94.7		146.1	135.6	139.8	115.6	94.5
Antidilutive share-based awards oustanding																				0.0		0.1	0.1	0.2
Payments of Dividends																				$ 36.3		$ 64.8	$ 46.1	$ 33.0
Common Stock, Dividends, Per Share, Declared																				$ 0.25	$ 0.21	$ 0.46	$ 0.39	$ 0.35
Accelerated Share Repurchases, Final Price Paid Per Share																				$ 151.59
Proceeds from (Repurchase of) Equity																				$ 500.0
Perrigo Co PLC [Member]
Stock Repurchase Program, Authorized Amount																									$ 2,000.0

[1] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[2] Includes Mylan defense-related fees of $15.6 million.

[3] Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.Twelve Months Ended June 28, 2014FirstQuarter(2) SecondQuarter(3) ThirdQuarter(4) FourthQuarter(5)Net sales$933.4 $979.0 $1,004.2 $1,144.2Gross profit$356.3 $360.7 $315.0 $415.7Net income (loss)$111.4 $(86.0) $48.1 $131.7Earnings (loss) per share(1): Basic$1.18 $(0.87) $0.36 $0.98Diluted$1.18 $(0.87) $0.36 $0.98Weighted average shares outstanding Basic94.2 98.7 133.7 133.8Diluted94.7 98.7 134.3 134.3

[4] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.

[5] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million

[6] Includes a loss contingency of $15.0 million related to Texas Medicaid and restructuring charges totaling $10.5 million

[7] Includes restructuring charges totaling $19.5 million

[8] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, and restructuring charges totaling $14.9 million

[9] Includes Elan transactions costs of $12.0 million